Melanotan-2

People run it to tan with far less sun — and, very often, for the side effects: spontaneous erections, a libido bump, and blunted appetite. That bundle is the whole point of MT-2 over MT-1. The honest framing up front: it’s unapproved, the human evidence is thin and old, and the case-report harms are not theoretical.

Here’s the contrast the MT-1 page sets up. MT-1 (afamelanotide) is selective — it leans on MC1R, the pigment receptor, and stays relatively in its lane. MT-2 is non-selective: it activates MC1R for tanning PLUS MC3R and MC4R, the same central melanocortin receptors PT-141 (bremelanotide) works through. That extra reach is exactly why MT-2 — unlike MT-1 — also throws spontaneous erections, raised libido, and appetite suppression. The shared MC4R pathway is the direct family link to PT-141; MT-2 is essentially the tanning peptide that accidentally became a libido peptide too.

A synthetic cyclic analog of α-MSH that activates melanocortin receptors broadly rather than selectively. MC1R in the skin drives melanin production (the tan). MC3R/MC4R in the central nervous system drive the rest: MC4R activation triggers erection and sexual arousal — in rabbit models via central neuronal nitric-oxide release — and suppresses appetite, while broader MC3R/MC4R/MC5R signaling underlies the autonomic load (nausea, flushing, blood-pressure and heart-rate changes). The non-selectivity isn’t a quirk; it’s the source of both the appeal and the risk.

This is the rough one. The everyday load is heavier than MT-1: nausea (often right after injection), facial flushing, and spontaneous erections are the common, expected effects, plus appetite loss and darkening of the skin generally. The serious, documented harms are what set MT-2 apart and why it’s graded the way it is. Pigment: it darkens and changes existing moles and freckles and can trigger new ones — case reports describe eruptive and rapidly-changing melanocytic naevi, some severely dysplastic, and melanotan use has been associated with melanoma. Any changing mole after using it warrants a dermatologist, not reassurance. Systemic: published case reports include rhabdomyolysis with acute kidney injury, posterior reversible encephalopathy syndrome (PRES), renal infarction, and priapism (a painful, prolonged erection that is a urological emergency). On top of all that the market is unregulated — counterfeits and unknown dosing are the norm. This is not a “well-tolerated” peptide.

Largely run standalone — it already does the tanning and the libido/appetite work in one molecule, so it isn’t paired into daily protocols. People sometimes compare it head-to-head with MT-1 (selective, calmer, pigment-only) and PT-141 (the as-needed, central-arousal cousin) rather than stack it. Combining it with anything that raises melanoma risk (heavy UV/sunbeds) is the opposite of cautious, since it’s already changing your moles.